Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOA: ColoAd1 in Resectable Solid Tumors
NCT02053220Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Jun 2013
- Primary completion
- Apr 2015
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of enadenotucirev in colon cancer, non-small cell lung cancer (NSCLC), bladder cancer and 1 more (2 cohorts), sponsored by Akamis Bio. Primary endpoint: Composite measure of viral delivery and spread. Started Jun 2013; status: completed.
02
Drugs
enadenotucirev
03
Conditions
colon cancernon-small cell lung cancer (NSCLC)bladder cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02053220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053220.